Suguru Yamasaki

This inventor holds 8 USPTO granted patents, plus 3 CIPO patents and 4 EPO patents. Top assignees: Riken Corporation, Sumitomo Pharma Co., Ltd., Sumitomo Chemical Company, Limited. Active years: 2022-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Suguru Yamasaki. Retrieved from https://idiyas.com/inventor/suguru-yamasaki

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 8

% Patents Active = 100.0

CIPO Patents = 3 (Patent Applications = 7)

EPO Patents = 4 (Patent Applications = 2)

Average Co-Inventor Count = 4.1

ph-index = 1

Forward Citations = 7(Granted Patents)

Company Filing History:

Sumitomo Pharma Co., Ltd.

patents

3 out of 6,961

Sumitomo Chemical Company, Limited

patents

4. 2 out of 110

Sumitomo Dainippon Pharma Co., Ltd.

where one patent can have more than one assignee

Years Active: 2022-2026

Loading Chart...

8 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12533382 - Composite including neural retina, retinal pigment epithelial cells, and hydrogel, and method for producing same (2026-01-27),

2. 12492373 - Production method for nerve tissue (2025-12-09),

3. 12291720 - Production method for retinal tissue (2025-05-06),

4. 12285543 - Human cell population comprising human retinal progenitor cells without an ISL1 gene for transplantation and methods of use thereof (2025-04-29),

5. 11684698 - Cell aggregate including retinal tissue and production method therefor (2023-06-27),

6. 11371016 - Method for producing retinal tissue (2022-06-28),

7. 11214772 - Production method for retinal tissue (2022-01-04),

8. 11214771 - Production method for nerve tissue (2022-01-04),

Title: Suguru Yamasaki: Innovator in Retinal Tissue Production

Introduction

Suguru Yamasaki is a prominent inventor based in Kobe, Japan. He has made significant contributions to the field of retinal tissue production, holding a total of six patents. His work focuses on innovative methods for producing retinal cells and tissues, which have important implications for medical science.

Latest Patents

Yamasaki's latest patents include a production method for retinal tissue. This invention outlines a method for producing retinal cells or retinal tissue through a series of specific steps. Another notable patent involves a human cell population comprising human retinal progenitor cells that lack an ISL1 gene, which is intended for transplantation. Additionally, he has developed a cell population suitable for transplanting retinal tissue, which includes retinal cells with a modified bipolar cell-regulating gene.

Career Highlights

Throughout his career, Suguru Yamasaki has worked with esteemed organizations such as Riken Corporation and Sumitomo Pharma Co., Ltd. His experience in these companies has allowed him to advance his research and contribute to the field of regenerative medicine.

Collaborations

Yamasaki has collaborated with notable individuals in his field, including Masayo Takahashi and Atsushi Kuwahara. These partnerships have further enriched his research and innovation efforts.

Conclusion

Suguru Yamasaki is a key figure in the development of retinal tissue production methods. His patents and collaborations reflect his commitment to advancing medical science and improving transplantation techniques.

Profile summary based on public USPTO records.